Abstract:To report 3 years clinical outcome of 121 nasopharyngeal carcinoma (NPC) patients treated with Tomotherapy in China. Between September 2007 and August 2010, 93 male and 28 female (total 121) newly diagnosed NPC patients were treated with TomoTherapy with IMRT/IGRT protocols. Median age was 42 (11 - 82), with 3 squamous and 118 non-keratinizing carcinomas. Distributions of clinical stages were: 11, 43, 43, 24 for Stage I, II, II, IVa according to Fouzhou 92's Staging and 8, 49, 40, 24 for Stage I, II, II, IVa-b according to UICC 2002 Staging. Patients were immobilized in a commercial thermoplastic cast from head to shoulders, and 3 mm thickness diagnostic CT scan slices of the head and neck protocol were acquired for targets and OARs contouring. Prescription dose was designed as 70 - 74 Gy in 33 fractions to gross tumor volume and positive lymph nodes, with 60 - 62.7 Gy in 33 fractions to high risk planning target volume, while delivering 52 - 56Gy in 33 fractions to low risk planning target volume. Thirty-one patients were treated with radiation therapy as a single modality, 35 with concurrent chemo-radiotherapy, 36 with EGFR monoclonal antibody (Cetuximab or Nimotuzumab), and 19 combined with chemotherapy and EGFR monoclonal antibody. Preliminary tumor response was observed and analyzed. Acute side-effects and late xerostomia were evaluated with the established RTOG/EORTC criteria. Local relapse-free survival (LRFS), nodal relapse-free survival (NRFS), distant metastasis-free survival (DMFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Average beam-on-time for NPC treatment was 457.6 sec/Fx (358.0- 696.1 sec). The median follow-up was 21 (6 - 42) months. Acute side-effects were evaluated, skin toxicities of Grade 0, 1, 2 and 3 were 5.0%, 74.4%, 15.7% and 4.9%; mucositis of Grade 0, 1, 2 and 3 were 0.8%, 37.2%, 57.9% and 4.1%; xerostomia of grade 0, 1, 2 and 3 were 3.3%, 53.7%, 43.0% and 0; respectively. Concurrent chemotherapy significantly increased the incidence of severe acute toxicities. The remission rates (CR+PR) noted 1 month after radiation therapy for primary tumor and positive lymph nodes were 95.0% and 99.0%. Parotid gland functions restored with time during study period, no grade 2 or more xerostomia was noted 12 months after radiation therapy. The LRFS, NRFS, DMFS and OS were 96.4%, 100%, 97.3% and 96.5% for one year; 94.6%, 100%, 93.2% and 92.6% for two years; 94.6%, 100%, 87.4 and 86.8% for three years, respectively. Incidence of severe acute toxicities and late xerostomia is relatively minor for NPC patients treated with helical tomotherapy which presents great advantages from both planning and delivery aspects for local control and reduction of side effects. Long-term clinical outcome for these patients is under investigation.

Significance of CT scan in the early follow-up after definitive radiotherapy of nasopharyngeal cancer

Parametric Contrast-Enhanced Ultrasound As an Early Predictor of Radiation-Based Therapeutic Response for Lymph Node Metastases of Nasopharyngeal Carcinoma.

18F-FLT and 18F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results.

Early prediction of tumor response after radiotherapy in combination with cetuximab in nasopharyngeal carcinoma using 99m Tc-duramycin imaging

[Application of 18F-FDG PET/CT Scan in Following-Up of Nasopharyngeal Carcinoma after Radiotherapy].

Local Regression and Control of T1-2 Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy.

Efficacy of Conventional Radiotherapy and Late Course Accelerated Hyperfractionationated Radiotherapy for Nasopharyngeal Carcinoma

Long-term Results of Nasopharyngeal Carcinoma Treated with Radiotherapy:1706 Cases Report

Clinical Study of Irradiation Combined with Late Course Chemotherapy in Nasopharyngeal Carcinoma

Scintigraphic Assessment of Parotid Function Prior to and after IMRT for Pantients with Nasopharygeal Carcinoma

Re-irradiation Using 3-Dimensional Conformal Radiation Therapy for Definitive Treatment of 140 Cases of Locally Recurrent Nasopharyngeal Carcinoma

Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up

Efficacy and Prognosis of CT-Guided Implantation of 125I Seeds As Salvage Treatment for Recurrent Nasopharyngeal Carcinoma after External Beam Radiotherapy--a Long-Term Experience at a Single Institution

Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.

[Concurrent Control Study of Different Radiotherapy for Primary Nasopharyngeal Carcinoma: Intensity-Modulated Radiotherapy Versus Conventional Radiotherapy].

Role of Chemoradiotherapy in Intermediate Prognosis Nasopharyngeal Carcinoma

Early response to chemoradiotherapy for nasopharyngeal carcinoma treatment: Value of dynamic contrast-enhanced 3.0 T MRI

Use of 18F-FDG PET/CT in the Diagnosis, Staging, Response Assessment and Prognosis of Nasopharyngeal Carcinoma: an Updated Review

Deletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non‐metastatic stage T4 nasopharyngeal carcinoma in IMRT era

The use of MR imaging to detect residual versus recurrentnasopharyngeal carcinoma following treatment withradiation therapy

Clinical Observations of 121 Nasopharyngeal Carcinoma Patients Treated with Helical Tomotherapy